

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 4 OCT 03 MATHDI removed from STN
NEWS 5 OCT 04 CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS 6 OCT 13 New CAS Information Use Policies Effective October 17, 2005
NEWS 7 OCT 17 STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAplus documents for use in third-party analysis and visualization tools
NEWS 8 OCT 27 Free KWIC format extended in full-text databases
NEWS 9 OCT 27 DIOGENES content streamlined
NEWS 10 OCT 27 EPFULL enhanced with additional content
NEWS 11 NOV 14 CA/CAplus - Expanded coverage of German academic research
NEWS 12 NOV 30 REGISTRY/ZREGISTRY on STN(R) enhanced with experimental spectral property data
NEWS 13 DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS 14 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 15 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 16 DEC 14 CA/CAplus to be enhanced with updated IPC codes
NEWS 17 DEC 16 MARPATprev will be removed from STN on December 31, 2005
NEWS 18 DEC 21 IPC search and display fields enhanced in CA/CAplus with the IPC reform
NEWS 19 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/USPAT2

NEWS EXPRESS DECEMBER 02 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 02 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * STN Columbus * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:12:42 ON 27 DEC 2005

| | | | |
|----------------------|------------|---------|--|
| => file reg | | | |
| COST IN U.S. DOLLARS | SINCE FILE | TOTAL | |
| FULL ESTIMATED COST | ENTRY | SESSION | |
| | 0.21 | 0.21 | |

FILE 'REGISTRY' ENTERED AT 12:12:47 ON 27 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 26 DEC 2005 HIGHEST RN 870675-00-6
DICTIONARY FILE UPDATES: 26 DEC 2005 HIGHEST RN 870675-00-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10821793\Struc 1.str



chain nodes :
6 7 8 9 10 11 12 18 19 20 21 22 23 24

Page 3


```
ring nodes :  
1 2 3 4 5 13 14 15 16 17  
chain bonds :  
5-6 6-7 6-21 7-8 8-9 9-10 9-22 10-11 11-12 12-13 12-23 17-18 18-19  
18-24 19-20  
ring bonds :  
1-2 1-5 2-3 3-4 4-5 13-14 13-17 14-15 15-16 16-17  
exact/norm bonds :  
1-2 1-5 2-3 3-4 4-5 6-7 6-21 7-8 9-10 9-22 10-11 12-13 12-23 13-14  
13-17 14-15 15-16 16-17 18-19 18-24 19-20  
exact bonds :  
5-6 8-9 11-12 17-18
```

Match level :

```
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS  
10:CLASS 11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS  
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS
```

L1 STRUCTURE UPLOADED

```
=> d  
L1 HAS NO ANSWERS  
L1 STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> l1  
SAMPLE SEARCH INITIATED 12:13:02 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 8 TO ITERATE
```

```
100.0% PROCESSED 8 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS: ONLINE **COMPLETE**  
BATCH **COMPLETE**  
PROJECTED ITERATIONS: 8 TO 329  
PROJECTED ANSWERS: 0 TO 0
```

L2 0 SEA SSS SAM L1

```
=> l1 full  
FULL SEARCH INITIATED 12:13:04 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 169 TO ITERATE
```

100.0% PROCESSED 169 ITERATIONS
 SEARCH TIME: 00.00.01

11 ANSWERS

L3 11 SEA SSS FUL L1

=> file caplus medline

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE TOTAL
 ENTRY SESSION
 161.33 161.54

FILE 'CAPLUS' ENTERED AT 12:13:11 ON 27 DEC 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 12:13:11 ON 27 DEC 2005

=> l3



L4 4 L3

=> dup rem l4

PROCESSING COMPLETED FOR L4

L5 4 DUP REM L4 (0 DUPLICATES REMOVED)

=> d abs ibib hitstr 1-4

L5 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
 GI


AB The invention relates to compds. I [Ar is a 5- to 10-membered aromatic ring having up to 4 heteroatoms O, S, NH, SO and SO₂, in which 1-3 ring atoms

are optionally substituted; R1, R2 are independently (un)substituted (hetero)alkyl, cycloalk(en)yl, cycloalk(en)yl-, aryl- or heteroaryl-(hetero)alkyl; R3, R3' are independently H, (un)substituted alkyl, halo-, sulfhydryl- or hydroxyalkyl, Ph or benzyl; or R3R3' is a ring; R4, R4' are independently H, (un)substituted (hetero)alkyl, cycloalkyl(hetero)alkyl, aryl or heterocycl; W is COCOR6, COCO2R6, COCONR62 (R6 is H, alkyl, (hetero)aryl, etc.) or a boryl group; T is alkyl, (hetero)aryl or (hetero)alkyl that inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. The invention further relates to processes for preparing these compds. and to pharmaceutical compns. containing them. Thus, peptide II was prepared via peptide coupling reactions in solution and shown to have HCV NS3-NS4A protease inhibitory activity ($K_i < 0.1 \mu\text{M}$ and $\text{IC}_{50} < 0.5 \mu\text{M}$).



ACCESSION NUMBER: 2005:347009 CAPLUS
 DOCUMENT NUMBER: 142:411657
 TITLE: Preparation of peptides as inhibitors of serine proteases, particularly HCV NS3-NS4A protease
 INVENTOR(S): Perni, Robert B.; Court, John J.; Britt, Shawn D.; Pitlik, Janos; Van Drie, John H.
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
 SOURCE: PCT Int. Appl., 150 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|--|----------|-----------------|------------|
| WO 2005035525 | A2 | 20050421 | WO 2004-US29093 | 20040907 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2005137139 | A1 | 20050623 | US 2004-936450 | 20040907 |
| PRIORITY APPLN. INFO.: | | | US 2003-500670P | P 20030905 |
| OTHER SOURCE(S): | MARPAT 142:411657 | | | |
| IT 850251-11-5P | RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) | | | |
| | (preparation of peptides as inhibitors of serine proteases, particularly HCV NS3-NS4A protease) | | | |
| RN 850251-11-5 | CAPLUS | | | |
| CN L-Prolinamide, 1H-imidazole-2-carbonyl-(2S)-2-cyclohexylglycyl-3-methyl-L-valyl-N-[(1S)-1-[(cyclopropylamino)oxoacetyl]butyl]-4-(1-naphthalenylxy)-(4R)-(9CI) (CA INDEX NAME) | | | | |

Absolute stereochemistry.



L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
GI



AB The invention relates to compds. I [the R groups are H (except R1, R3) or various groups, i.e., R5, R5' are alkyl, halo-, mercapto- or hydroxyalkyl, (un)substituted Ph or benzyl or R5/R5' may form a ring; R2, R4, R7 are (un)substituted alkyl, cycloalkylalkyl or arylalkyl; R1, R3 are (un)substituted alkyl, cycloalkyl, cycloalkylalkyl, etc.; R9, R9', R10, R10' are -X-Y-Z, where X is a bond, alkylene, O, S or imino, Y is a bond, CH₂, CO, COCO, SO, SO₂ or sulfinylimino, Z is H, alkyl, aryl, etc.; V is CO, SO or SO₂, R is CO, SO, SO₂, imino, O or a bond; T is alkyl, aryl, etc; W is an acyl or boryl group] or their pharmaceutically-acceptable salts that inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Thus, peptide II was prepared by


peptide coupling reactions in solution and showed Ki in the range 0.5-1 μM for inhibition of HCV.

ACCESSION NUMBER: 2004:902372 CAPLUS
 DOCUMENT NUMBER: 141:350404
 TITLE: Preparation of peptides as inhibitors of serine proteases, particularly HCV NS3-NS4A protease
 INVENTOR(S): Farmer, Luc J.; Perni, Robert P.; Bhiseetti, Govinda Rao; Wilson, Keith P.
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Incorporated, USA
 SOURCE: PCT Int. Appl., 116 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|------------|
| WO 2004092162 | A1 | 20041028 | WO 2004-US11012 | 20040409 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG | | | | |
| US 2004018986 | A1 | 20040129 | US 2003-412600 | 20030411 |
| CA 2521678 | AA | 20041028 | CA 2004-2521678 | 20040409 |
| US 2005090450 | A1 | 20050428 | US 2004-821793 | 20040409 |
| PRIORITY APPLN. INFO.: | | | US 2003-412600 | A 20030411 |
| | | | US 2003-513765P | P 20031023 |
| | | | US 2002-371846P | P 20020411 |
| | | | WO 2004-US11012 | W 20040409 |


OTHER SOURCE(S): MARPAT 141:350404
 IT 777087-23-7P 777087-37-3P 777087-38-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of peptides as inhibitors of serine proteases, particularly HCV NS3-NS4A protease)
 RN 777087-23-7 CAPLUS
 CN L-Prolinamide, 1H-imidazole-2-carbonyl-(2S)-2-cyclohexylglycyl-L-valyl-N-[1-[(cyclopropylamino)oxoacetyl]butyl]-3-ethyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 777087-37-3 CAPLUS
CN L-Prolinamide, 1H-imidazole-2-carbonyl-(2S)-2-cyclohexylglycyl-3-methyl-L-valyl-3-cyclohexyl-N-[(1S)-1-[(cyclopropylamino)oxoacetyl]butyl]-, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 777087-38-4 CAPLUS
CN L-Prolinamide, 1H-imidazole-2-carbonyl-(2S)-2-cyclohexylglycyl-3-methyl-L-valyl-N-[(1S)-1-[(cyclopropylamino)oxoacetyl]butyl]-3-(1-methylethyl)-, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
AB The invention discloses peptidomimetic compds. which inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The compds. of the invention have a bridged bicyclic moiety at the P2 position. The invention further discloses compns. comprising these compds., either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also discloses methods of treating an HCV infection in a patient by administering a composition comprising a compound of the invention. Preparation of compds. of the invention is described.

ACCESSION NUMBER: 2003:58112 CAPLUS

DOCUMENT NUMBER: 138:117634

TITLE: Bridged bicyclic peptidomimetic serine protease inhibitors, and use as antiviral agents against hepatitis C virus

INVENTOR(S): Farmer, Luc; Pitlik, Janos; Perni, Robert; Courtney, Lawrence; Van Drie, John

PATENT ASSIGNEE(S) : Vertex Pharmaceuticals Incorporated, USA
 SOURCE: PCT Int. Appl., 91 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|------|----------|-----------------|------------|
| WO 2003006490 | A1 | 20030123 | WO 2002-US22027 | 20020711 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2449504 | AA | 20030123 | CA 2002-2449504 | 20020711 |
| US 2003119752 | A1 | 20030626 | US 2002-193048 | 20020711 |
| US 6909000 | B2 | 20050621 | | |
| EP 1404704 | A1 | 20040407 | EP 2002-749965 | 20020711 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE | | | | |
| CN 1525979 | A | 20040901 | CN 2002-813816 | 20020711 |
| JP 2005522409 | T2 | 20050728 | JP 2003-512260 | 20020711 |
| ZA 2003009156 | A | 20050527 | ZA 2003-9156 | 20031125 |
| NO 2004000127 | A | 20040311 | NO 2004-127 | 20040112 |
| PRIORITY APPLN. INFO.: | | | US 2001-304615P | P 20010711 |
| | | | US 2001-322714P | P 20010917 |
| | | | WO 2002-US22027 | W 20020711 |


OTHER SOURCE(S) : MARPAT 138:117634

IT 488781-08-4 488781-09-5
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (bridged bicyclic peptidomimetic serine protease inhibitors, and use as
 antiviral agents against hepatitis C virus)

RN 488781-08-4 CAPLUS

CN 2-Azabicyclo[2.2.1]heptane-3-carboxamide, 1H-imidazole-2-carbonyl-(2S)-2-
 cyclohexylglycyl-3-methyl-L-valyl-N-[(1S)-1-[oxo[[1S]-1-
 phenylethyl]amino]acetyl]butyl]-, (1R,3S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 488781-09-5 CAPLUS

CN 2-Azabicyclo[2.2.1]heptane-3-carboxamide, 1H-imidazole-2-carbonyl-(2S)-2-cyclohexylglycyl-3-methyl-L-valyl-N-[(1S)-1-[(cyclopropylamino)oxoacetyl]butyl]-, (1R,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN
GI



AB Peptidomimetic compds. R9-L-(NR8-R7-CO)nNR6-R5-CO-NX-CONR4-R3-CO-R-CONR1R2
[R is a bond or CF₂; R1 is H, (un)substituted an aliphatic, cyclic, or aromatic group; R2, R9 are (un)substituted aliphatic, cyclic, or aromatic groups; R3, R5,
R7 are (un)substituted 1,1- or 1,2-cycloalkylene or -heterocyclylene, methylene or ethylene; R4, R6, R8 and R10 are H or an optionally substituted aliphatic group; NX is an (un)substituted cyclic azaheterocycl or azaheterocyclenyl having the unsatn. in the ring distal to ring bearing the -R5-C(O)-N moiety and to which the -CONR4- moiety is attached; L is CO, O₂C, NR₁₀CO, SO₂, or NR₁₀SO₂; n is 0 or 1] or pharmaceutically acceptable salts or prodrugs were prepared for use as protease inhibitors, particularly as hepatitis C NS3 protease inhibitors. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compds. having anti HCV activity and a pharmaceutically acceptable carrier. Thus, compd I was prepared and assayed for HCV serine protease inhibitory activity in combination with interferons. When used as a single drug treatment, I exhibits an IC₅₀ of 0.48 μM and interferon-α 2B is 2.19 U.

ACCESSION NUMBER: 2002:171885 CAPLUS

DOCUMENT NUMBER: 136:232547

TITLE: Preparation of peptidomimetic protease inhibitors

INVENTOR(S): Babine, Robert Edward; Chen, Shu Hui; Lamar, Jason Eric; Snyder, Nancy June; Sun, Xicheng David; Tebbe, Mark Joseph; Victor, Frantz; Wang, Q. May; Yip, Yvonne Yee Mai; Collado, Ivan; Garcia-Paredes, Cristina; Parker, Raymond Samuel, III; Jin, Ling; Guo, Deqi; Glass, John Irvin

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 424 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--|------|----------|-----------------|----------|
| WO 2002018369 | A2 | 20020307 | WO 2001-US26008 | 20010831 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, | | | | |

KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
 IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
 GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2419607 AA 20020307 CA 2001-2419607 20010831
 AU 2001088318 A5 20020313 AU 2001-88318 20010831
 EP 1320540 A2 20030625 EP 2001-968040 20010831
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004517047 T2 20040610 JP 2002-523884 20010831
 BR 2001013666 A 20050927 BR 2001-13666 20010831
 NO 2003000928 A 20030416 NO 2003-928 20030227
 ZA 2003001641 A 20040621 ZA 2003-1641 20030227
 US 2005197299 A1 20050908 US 2004-344112 20041217
 PRIORITY APPLN. INFO.: US 2000-229398P P 20000831
 US 2001-277641P P 20010321
 WO 2001-US26008 W 20010831

OTHER SOURCE(S): MARPAT 136:232547

IT 402957-63-5P 402957-89-5P 402957-90-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptidomimetic protease inhibitors)

RN 402957-63-5 CAPPLUS

CN Cyclopenta[c]pyrrole-1-carboxamide, 1H-imidazole-2-carbonyl-(2S)-2-cyclohexylglycyl-3-methyl-L-valyl-N-[(1S)-1-[(cyclopropylamino)oxoacetyl]butyl]-4,4-difluoroctahydro-, (1S,3aR,6aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 402957-89-5 CAPPLUS

CN Cyclopenta[c]pyrrole-1-carboxamide, 1-methyl-1H-imidazole-2-carbonyl-(2S)-2-cyclohexylglycyl-3-methyl-L-valyl-N-[(1S)-1-[(cyclopropylamino)oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 402957-90-8 CAPLUS

CN Cyclopenta[c]pyrrole-1-carboxamide, 1H-imidazole-2-carbonyl-(2S)-2-cyclohexylglycyl-3-methyl-L-valyl-N-[(1S)-1-[(cyclopropylamino)oxoacetyl]butyl]octahydro-, (1S,3aR,6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 402960-13-8P 402960-14-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of peptidomimetic protease inhibitors)

RN 402960-13-8 CAPLUS

CN Cyclopenta[c]pyrrole-1-carboxamide, 1-(phenylmethyl)-1H-imidazole-2-carbonyl-(2S)-2-cyclohexylglycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-1-hydroxy-2-oxoethyl]butyl]-4,4-difluoroctahydro-, (1S,3aR,6aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 402960-14-9 CAPLUS

CN Cyclopenta[c]pyrrole-1-carboxamide, 1H-imidazole-2-carbonyl-(2S)-2-cyclohexylglycyl-3-methyl-L-valyl-N-[(1S)-1-[2-(cyclopropylamino)-1-hydroxy-2-oxoethyl]butyl]-4,4-difluoroctahydro-, (1S,3aR,6aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> log h

COST IN U.S. DOLLARS

SINCE FILE
ENTRY

FULL ESTIMATED COST

27.49
189.03

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE
ENTRY

CA SUBSCRIBER PRICE

-2.92
-2.92

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 12:23:40 ON 27 DEC 2005

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626